MedTrace Logo

A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

NCT07460375 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2026-03-10

No results posted yet for this study

Summary

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

Conditions

Interventions

DRUG

LCB02A

CLDN18.2-directed human monoclonal antibody (Ab) linked to a topoisomerase I inhibiting payload.

Sponsors & Collaborators

  • AntibodyChem Biosciences, Inc.

    collaborator UNKNOWN

  • LigaChem Biosciences, Inc.

    lead INDUSTRY

Principal Investigators

  • Rodrigo Ruiz Soto, M.D. · LigaChem Biosciences

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-31
Primary Completion
2030-02-28
Completion
2030-08-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07460375 on ClinicalTrials.gov